CN111787932A - 使用免疫调节性乳球菌属细菌菌株治疗免疫病症的组合物和方法 - Google Patents

使用免疫调节性乳球菌属细菌菌株治疗免疫病症的组合物和方法 Download PDF

Info

Publication number
CN111787932A
CN111787932A CN201880073835.6A CN201880073835A CN111787932A CN 111787932 A CN111787932 A CN 111787932A CN 201880073835 A CN201880073835 A CN 201880073835A CN 111787932 A CN111787932 A CN 111787932A
Authority
CN
China
Prior art keywords
immunomodulatory
lactococcus
strain
bacterial composition
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880073835.6A
Other languages
English (en)
Chinese (zh)
Inventor
B.古德曼
H.波尼奇特拉
A.伊塔诺
M.博默
T.A.科尔马克
M.西佐瓦
C.贝斯-吉安格雷科
D.麦克黑尔
K.拉马尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epiva Biosciences Inc
Original Assignee
Epiva Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epiva Biosciences Inc filed Critical Epiva Biosciences Inc
Publication of CN111787932A publication Critical patent/CN111787932A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880073835.6A 2017-11-15 2018-11-15 使用免疫调节性乳球菌属细菌菌株治疗免疫病症的组合物和方法 Pending CN111787932A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762586604P 2017-11-15 2017-11-15
US62/586604 2017-11-15
US201862660693P 2018-04-20 2018-04-20
US62/660693 2018-04-20
US201862661459P 2018-04-23 2018-04-23
US62/661459 2018-04-23
US201862721941P 2018-08-23 2018-08-23
US62/721941 2018-08-23
PCT/US2018/061297 WO2019099682A1 (en) 2017-11-15 2018-11-15 Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains

Publications (1)

Publication Number Publication Date
CN111787932A true CN111787932A (zh) 2020-10-16

Family

ID=66539145

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880073835.6A Pending CN111787932A (zh) 2017-11-15 2018-11-15 使用免疫调节性乳球菌属细菌菌株治疗免疫病症的组合物和方法

Country Status (13)

Country Link
US (2) US11266700B2 (es)
EP (1) EP3710024A1 (es)
JP (1) JP2021502970A (es)
KR (1) KR20200090189A (es)
CN (1) CN111787932A (es)
AU (1) AU2018367596A1 (es)
BR (1) BR112020009133A2 (es)
CA (1) CA3082578A1 (es)
CO (1) CO2020007142A2 (es)
MX (1) MX2020004934A (es)
SA (1) SA520411910B1 (es)
TW (1) TW201922270A (es)
WO (1) WO2019099682A1 (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442472A (zh) * 2020-11-30 2021-03-05 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
CN117581993A (zh) * 2020-12-28 2024-02-23 郑州大学 乳酸菌提取物、其制备及其抗氧化抗辐射应用
CN118006515A (zh) * 2024-04-08 2024-05-10 中国农业大学 一株乳酸乳球菌及其在制备治疗牛乳腺炎的药物中的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536969A (ja) 2017-10-12 2020-12-17 アンフィヴェナ セラピューティクス，インク． Ｃｄ３結合タンパク質の投薬レジメン
WO2019099682A1 (en) 2017-11-15 2019-05-23 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
MX2021015427A (es) * 2019-06-11 2022-01-24 Evelo Biosciences Inc Vesiculas extracelulares microbianas procesadas.
WO2021022070A2 (en) * 2019-07-31 2021-02-04 Sanford Burnham Prebys Medical Discovery Institute Prebiotic-induced anti-tumor immunity
US20230190831A1 (en) * 2020-04-17 2023-06-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
KR102523743B1 (ko) * 2020-07-20 2023-04-19 건국대학교 산학협력단 락토코커스 락티스 kc24 균주를 포함하는 퇴행성 신경질환 예방 또는 치료용 조성물
KR102461600B1 (ko) 2020-07-21 2022-11-02 주식회사 피토맵 N-당질화 돌연변이 벼, 이의 제조방법 및 이를 이용한 단백질 생산용 벼의 제조방법
CN111803476A (zh) * 2020-08-14 2020-10-23 华中科技大学协和深圳医院 芬戈莫德用于抑制革兰阳性细菌活性的用途
JP2022060035A (ja) * 2020-10-02 2022-04-14 国立研究開発法人産業技術総合研究所 腸管の抗老化用組成物
WO2022114528A1 (ko) * 2020-11-30 2022-06-02 주식회사 엠디헬스케어 락토코커스 락티스 유래 소포를 포함하는 호산구성 염증질환 또는 th2 과민성 면역질환 예방, 치료, 또는 개선용 조성물
US12599639B2 (en) 2021-01-26 2026-04-14 Megmilk Snow Brand Co., Ltd. Joint function-improving composition
KR102391017B1 (ko) * 2021-07-13 2022-04-29 한국식품연구원 락토코커스 락티스 WiKim0133을 포함하는 암의 예방, 개선 또는 치료용 조성물
KR102700114B1 (ko) * 2021-08-11 2024-08-29 박병희 신규한 락토코쿠스 락티스 서브스페이시스 크레모리스 및 이의 용도
KR102696109B1 (ko) * 2021-10-06 2024-08-16 국립부경대학교 산학협력단 락토코커스 락티스 생육 촉진용 조성물
CN114540235B (zh) * 2022-03-04 2023-10-31 中国海洋大学 一种诱导乳酸菌休眠态的方法及其应用
WO2023192361A1 (en) * 2022-03-31 2023-10-05 Incelldx, Inc. Methods of treating a subject for fibromyalgia and compositions for use in the same
AU2023277074A1 (en) 2022-05-27 2024-12-19 Asahi Group Holdings, Ltd. Fpr2 agonist containing outer membrane vesicles derived from lactic acid bacterium
KR20250060636A (ko) * 2023-10-26 2025-05-07 (주)씨앤에스알 제대혈 유래 조혈모세포 이식 및 면역 세포 신장 기술에 기반한 초고도화된 인간면역화 마우스 모델 제작과 그의 제조 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017208A1 (en) * 2013-07-12 2015-01-15 National Yang-Ming University Lactic acid bacterium having immunomodulatory and anti-allergic effects
JP2015145356A (ja) * 2014-02-04 2015-08-13 株式会社東書エステート 微粒子化した乳酸菌（ラクトコッカス・ラクティス・サブスピーシーズクレモリスｈ−６１株（ｎｉｔｅｂｐ−０１７８７））を有効成分として含有する免疫調整剤並びにこれを含有する薬剤及び食品

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US7101565B2 (en) * 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
EP1593309B1 (en) * 2004-05-07 2014-06-25 Friesland Brands B.V. Dairy product with at least one characteristic of a dairy product mixture
JP2007269737A (ja) * 2006-03-31 2007-10-18 Morinaga Milk Ind Co Ltd インターロイキン産生調節剤、該インターロイキン産生調節剤を含む医薬組成物及び飲食品、並びにその製造方法
FI20075539A7 (fi) * 2007-07-12 2009-01-13 Valio Oy Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
WO2016144139A2 (ko) * 2015-03-11 2016-09-15 주식회사 엠디헬스케어 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물
EP3081227A1 (en) * 2015-04-15 2016-10-19 Institut National De La Recherche Agronomique Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics
US20200138878A1 (en) 2017-07-06 2020-05-07 Probionase Therapies Inc. Probiotic-based treatment of resistant chronic rhinosinusitis
WO2019099682A1 (en) 2017-11-15 2019-05-23 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017208A1 (en) * 2013-07-12 2015-01-15 National Yang-Ming University Lactic acid bacterium having immunomodulatory and anti-allergic effects
JP2015145356A (ja) * 2014-02-04 2015-08-13 株式会社東書エステート 微粒子化した乳酸菌（ラクトコッカス・ラクティス・サブスピーシーズクレモリスｈ−６１株（ｎｉｔｅｂｐ−０１７８７））を有効成分として含有する免疫調整剤並びにこれを含有する薬剤及び食品

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B C LARISCH, D PONCELET, C P CHAMPAGNE, R J NEUFELD: "Microencapsulation of Lactococcus lactis subsp. cremoris", JOURNAL OF MICROENCAPSULATION, vol. 11, no. 2, XP000425619 *
CHIH-HSIEN YANG, CHIEN-CHEN WU, WEI-SHEN CHENG, MING-CHUAN CHUNG, YING-CHIEH TSAI, CHUAN-HSIUNG CHANG: "A17, the First Sequenced Strain of Lactococcus lactis subsp. cremoris with Potential Immunomodulatory Functions", GENOME ANNOUNCEMENTS, vol. 3, no. 1, pages 01563 - 14 *
HUI-CHING MEI, YEN-WENN LIU, YI-CHIN CHIANG, SHIOU-HUEI CHAO, NAI-WEN MEI, YU-WEN LIU, YING-CHIEH TSAI: "Immunomodulatory Activity of Lactococcus lactis A17 from Taiwan Fermented Cabbage in OVA-Sensitized BALB/c Mice", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2013, pages 287803 *
P J LOOIJESTEIJN, W H VAN CASTEREN, R TUINIER, C H DOESWIJK-VORAGEN, J HUGENHOLTZ: "Influence of different substrate limitations on the yield, composition and molecular mass of exopolysaccharides produced by Lactococcus lactis subsp. cremoris in continuous cultures", JOURNAL OF APPLIED MICROBIOLOGY2000,89, 116ˇ122=2000 THE SOCIETY FOR APPLIED MICROBIOLOGY, vol. 89, no. 2 *
TETSU SUGIMURA, KENTA JOUNAI, KONOMI OHSHIO, TAKAAKI TANAKA, MASAHIRO SUWA, DAISUKE FUJIWARA: "Immunomodulatory effect of Lactococcus lactis JCM5805 on human plasmacytoid dendritic cells", CLINICAL IMMUNOLOGY, vol. 149, no. 3, pages 509 - 518 *
YAYOI GOTOH 等: "effect of orally administered exopolysaccharides produced by Lactococcus lactis subsp. cremoris FC on a mouse model of dermatitis induced by repeated exposure to 2,4,6-trinitro-1-chlorobenzene", JOURNAL OF FUCTIONAL FOODS, vol. 35, pages 43 - 50 *
贺平 等: "Exosome 及其他胞外囊泡在病原微生物中的研究进展", 中国病原生物 学杂志, vol. 12, no. 04, pages 384 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442472A (zh) * 2020-11-30 2021-03-05 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
CN117581993A (zh) * 2020-12-28 2024-02-23 郑州大学 乳酸菌提取物、其制备及其抗氧化抗辐射应用
CN118006515A (zh) * 2024-04-08 2024-05-10 中国农业大学 一株乳酸乳球菌及其在制备治疗牛乳腺炎的药物中的应用

Also Published As

Publication number Publication date
JP2021502970A (ja) 2021-02-04
WO2019099682A9 (en) 2019-07-04
SA520411910B1 (ar) 2023-12-11
EP3710024A1 (en) 2020-09-23
TW201922270A (zh) 2019-06-16
CO2020007142A2 (es) 2020-06-19
BR112020009133A2 (pt) 2020-10-13
WO2019099682A1 (en) 2019-05-23
US11266700B2 (en) 2022-03-08
AU2018367596A1 (en) 2020-05-21
CA3082578A1 (en) 2019-05-23
KR20200090189A (ko) 2020-07-28
US20220211773A1 (en) 2022-07-07
US20190231829A1 (en) 2019-08-01
MX2020004934A (es) 2020-12-03

Similar Documents

Publication Publication Date Title
US20220211773A1 (en) Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
US10702561B2 (en) Pharmaceutical compositions comprising a Blautia strain
US11090341B2 (en) Compositions and methods for treating cancer and immune disorders using Veillonella bacteria
TWI840334B (zh) 源自普雷沃菌(prevotella)之胞外囊泡
TWI814739B (zh) 細菌胞外囊泡
CN111712260A (zh) 使用毛螺菌科细菌治疗免疫病症的组合物和方法
TW202128198A (zh) 分泌型微生物胞外囊泡
TW202140051A (zh) 具有改善的崩散譜之固體劑型
WO2019178490A1 (en) Compositions and methods for treating cancer and inflammation using klebsiella oxytoca
WO2019178494A1 (en) Compositions and methods for treating cancer and inflammation using tyzzerella nexilis
WO2019178487A2 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201016

WD01 Invention patent application deemed withdrawn after publication